Drugs / MAR002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07195175 | Aug 2025 → Jul 2026 overdue | acromegaly | Marea Therapeutics | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07641179 | Jul 2026 → Aug 2027 expected | acromegaly | Marea Therapeutics | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | Marea Therapeutics | Results Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026 mareatx.com ↗
MAR002 demonstrates deep and durable IGF-1 suppression up to 64% with favorable PK properties potentially enabling once every two-week dosing |
| 2026-01-13 | Marea Therapeutics | Results Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile mareatx.com ↗ |
| 2025-07-14 | Marea Therapeutics | Results Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025 mareatx.com ↗
Compared head-to-head to pegvisomant, a single dose of MAR002 resulted in a similar maximum IGF-1 suppression, but with a considerably longer duration of effect. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAR002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07195175 ↗ |
| Route | Subcutaneous | “subcutaneous (SC) administration of MAR002” NCT07195175 ↗ |